| Followers | 5 |
| Posts | 593 |
| Boards Moderated | 0 |
| Alias Born | 06/11/2010 |
Sunday, August 06, 2017 8:10:38 AM
"ILJIN's Hyuek Joon Lee is on AUPH's board of directors. ILJIN knows about any of the Voclosporin stories definitely better than BR, humour412, socialidiocies and Flyingtrader. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20+% or 5,185,185 shares of the 25,645,000 shares offered publicly on 03-13-2017? AUPH is good, isn't it? LJIN owns 17.35% of AUPH (14,205,457 shares) now after it added 5,185,185 shares at $6.75 in March. I don't think Katrina's confidence on AUPH would be shaken by BR and humour412."
https://relationshipscience.com/hyuek-joon-lee-p157816980
Dr. Hyuek Joon Lee is the Director of New Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas investments, joint ventures and subsidiaries. As of October 2014 he joined the board of directors of Life Science Enterprises in Massachusetts, ..." Link: http://insiders.morningstar.com/trading/executive-profile.action?t=0P0000BLCT&PersonId=PS0000A8VP&flag=Director&insider=Hyuek_Lee&culture=en-CA&productcode=CAN&ops=clear&cur=
This is Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
https://relationshipscience.com/hyuek-joon-lee-p157816980
Dr. Hyuek Joon Lee is the Director of New Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas investments, joint ventures and subsidiaries. As of October 2014 he joined the board of directors of Life Science Enterprises in Massachusetts, ..." Link: http://insiders.morningstar.com/trading/executive-profile.action?t=0P0000BLCT&PersonId=PS0000A8VP&flag=Director&insider=Hyuek_Lee&culture=en-CA&productcode=CAN&ops=clear&cur=
This is Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Recent AUPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:04:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:03:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:07:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 01:20:50 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 05/11/2026 01:15:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 12:23:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:22:07 PM
- Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress • Business Wire • 05/07/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:31:08 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/13/2026 11:27:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
